Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methylphenidate in Childhood Apraxia of Speech
Sponsor: Murdoch Childrens Research Institute
Summary
The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.
Official title: A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
Key Details
Gender
All
Age Range
6 Years - 12 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2022-03-14
Completion Date
2025-10-27
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
Methylphenidate Hydrochloride
Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
Placebo
Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
Locations (1)
Murdoch Children's Research Institute
Parkville, Victoria, Australia